FrancophonIA/ELRC3.0 huggingface dataset:
English: The most common side effects with Anoro Ellipta (which may affect up to 1 in 10 people) are upper respiratory tract infections (nose and throat infection), urinary tract infections (infection of the structures that carry urine), pharyngitis (inflammation of the throat), sinusitis (inflammation of the sinuses), nasopharyngitis (inflammation of the nose and throat), headache, cough, oropharyngeal pain (pain in the mouth and throat), constipation and dry mouth.
Slovenian: Najpogostejši neželeni učinki zdravila Anoro Ellipta (ki se lahko pojavijo pri največ 1 bolniku od 10) so okužbe zgornjih dihal (okužbe nosu in žrela), okužbe sečil (okužbe struktur za odvajanje urina), faringitis (vnetje žrela), sinuzitis (vnetje sinusov), nazofaringitis (vnetje nosu in žrela), glavobol, kašelj, orofaringealna bolečina (bolečina v ustih in žrelu), zaprtje in suha usta.
English: What measures are being taken to ensure the safe and effective use of Anoro Ellipta?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Anoro Ellipta?
English: Anoro Ellipta received a marketing authorisation valid throughout the EU on 8 May 2014.
Slovenian: Za zdravilo Anoro Ellipta je bilo 8. maja 2014 izdano dovoljenje za promet, veljavno po vsej EU.
English: Side effects reported with Anoro Ellipta are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Anoro Ellipta, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: As for all medicines, data on the use of Anoro Ellipta are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Anoro Ellipta stalno spremljajo.
English: The Agency also noted that there were no major safety concerns with Anoro Ellipta, with side effects being manageable, although the long-term safety data so far are limited.
Slovenian: Ugotovila je tudi, da ni večjih pomislekov glede varnosti zdravila Anoro Ellipta, saj so njegovi neželeni učinki obvladljivi, čeprav so podatki o dolgoročni varnosti zdravila trenutno omejeni.
English: Umeclidinium is a muscarinic receptor antagonist.
Slovenian: Umeklidinij je antagonist muskarinskih receptorjev.
English: Anoro Ellipta is used for maintenance (regular) treatment.
Slovenian: Zdravilo Anoro Ellipta se uporablja za vzdrževalno (redno) zdravljenje.
English: Vilanterol is a long-acting beta-2 adrenergic agonist.
Slovenian: Vilanterol je dolgodelujoči agonist adrenergičnih receptorjev beta2.
English: It works by attaching to beta-2 adrenergic receptors found in the muscle cells of many organs including the airways in the lungs.
Slovenian: Deluje tako, da se veže na adrenergične receptorje beta2 v mišičnih celicah številnih organov, vključno z dihalnimi potmi v pljučih.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Anoro Ellipta have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Anoro Ellipta upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Anoro Ellipta is a medicine used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults.
Slovenian: Zdravilo Anoro Ellipta se uporablja za lajšanje simptomov kronične obstruktivne pljučne bolezni (KOPB) pri odraslih.
English: An overview of Anoro Ellipta and why it is authorised in the EU
Slovenian: Pregled zdravila Anoro Ellipta in zakaj je odobreno v EU
English: The higher dose combination of umeclidinium and vilanterol did not consistently lead to better improvements in lung function than Anoro Ellipta to justify its use.
Slovenian: Kombinacija z večjim odmerkom umeklidinija in vilanterola ni vedno privedla do večjega izboljšanja delovanja pljuč kot zdravilo Anoro Ellipta, zaradi česar ni mogoče upravičiti njene uporabe.
English: Why is Anoro Ellipta authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Anoro Ellipta odobreno v EU?
English: Anoro Ellipta also increased FEV1 by an average of up to 95 ml more than vilanterol alone and by 52 ml more than umeclidinium bromide alone.
Slovenian: Zdravilo Anoro Ellipta je tudi povečalo vrednost FEV1 za povprečno do 95 ml več kot sam vilanterol in za 52 ml več kot sam umeklidinijev bromid.
English: What benefits of Anoro Ellipta have been shown in studies?
Slovenian: Kakšne koristi zdravila Anoro Ellipta so se pokazale v študijah?
English: The active substances in Anoro Ellipta, umeclidinium and vilanterol, work in different ways to widen the airways and improve breathing in COPD.
Slovenian: Učinkovini v zdravilu Anoro Ellipta, umeklidinij in vilanterol, na različna načina širita dihalne poti in izboljšujeta dihanje pri KOPB.
English: Each inhalation provides 55 micrograms of umeclidinium (as umeclidinium bromide) and 22 micrograms of vilanterol.
Slovenian: Z enim vdihom se dovede 55 mikrogramov umeklidinija (v obliki umeklidinijevega bromida) in 22 mikrogramov vilanterola.
English: What is Anoro Ellipta and what is it used for?
Slovenian: Kaj je zdravilo Anoro Ellipta in za kaj se uporablja?
English: Other information about Anoro Ellipta
Slovenian: Druge informacije o zdravilu Anoro Ellipta
English: Muscarinic receptor antagonists and long-acting beta-2 agonists are commonly combined in the management of COPD.
Slovenian: Kombinacija antagonistov muskarinskih receptorjev in dolgodelujočih agonistov beta2 se pogosto uporablja za obvladovanje KOPB.
English: What are the risks associated with Anoro Ellipta?
Slovenian: Kakšna tveganja so povezana z zdravilom Anoro Ellipta?
English: The Agency concluded that Anoro Ellipta was shown to be effective at improving lung function and the symptoms of COPD when compared with placebo or the single components as well as with tiotropium.
Slovenian: Zaključila je, da se je zdravilo Anoro Ellipta izkazalo za učinkovito pri izboljševanju delovanja pljuč in simptomov KOPB v primerjavi s placebom, posameznima učinkovinama in tiotropijem.
English: Anoro Ellipta and a higher-dose combination of umeclidinium and vilanterol (113 micrograms/22 micrograms) were compared with placebo (a dummy treatment), vilanterol alone, umeclidinium alone or another COPD medicine called tiotropium in 5 main studies.
Slovenian: V petih glavnih študijah so zdravilo Anoro Ellipta in kombinacijo z večjim odmerkom umeklidinija (113 mikrogramov) in vilanterola (22 mikrogramov) primerjali s placebom (zdravilom brez učinkovine), vilanterolom samim, umeklidinijem samim ali drugim zdravilom za zdravljenje KOPB, imenovanim tiotropij.
English: Results showed that Anoro Ellipta improved lung function by an average FEV1 of 167 ml more than placebo after 24 weeks of treatment.
Slovenian: Rezultati so pokazali, da je zdravilo Anoro Ellipta po 24 tednih zdravljenja izboljšalo delovanje pljuč v smislu povečanja povprečne vrednosti FEV1 za 167 ml več kot placebo.
English: When umeclidinium is inhaled, it also relaxes the muscles of the airways.
Slovenian: Ko bolnik vdihne umeklidinij, ta sprosti tudi mišice dihalnih poti.
English: Anoro Ellipta contains the active substances umeclidinium bromide and vilanterol.
Slovenian: Zdravilo vsebuje učinkovini umeklidinijev bromid in vilanterol.
English: Anoro Ellipta was also shown to improve breathlessness when compared with placebo.
Slovenian: Zdravilo Anoro Ellipta je v primerjavi s placebom tudi olajšalo težko dihanje.
English: Anoro Ellipta can only be obtained with a prescription.
Slovenian: Predpisovanje in izdaja zdravila Anoro Ellipta je le na recept.
English: How is Anoro Ellipta used?
Slovenian: Kako se zdravilo Anoro Ellipta uporablja?
English: The average increase in FEV1 with Anoro Ellipta was 60, 90 and 112 ml more than with tiotropium after 24 weeks of treatment in the three studies where Anoro Ellipta was compared with tiotropium.
Slovenian: V treh študijah, v katerih so zdravilo Anoro Ellipta primerjali s tiotropijem, se je vrednost FEV1 pri zdravilu Anoro Ellipta po 24 tednih zdravljenja v povprečju povečala za 60 ml, 90 ml in 112 ml več kot pri tiotropiju.
English: How does Anoro Ellipta work?
Slovenian: Kako zdravilo Anoro Ellipta deluje?
English: Pack size bottle (HDPE)
Slovenian: Steklenička (HDPE) 100 tablet
English: (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging
Slovenian: Jakost Farmacevtska oblika Pot uporabe Ovojnina
English: In Italy: Nubriveo
Slovenian: V Italiji: Nubriveo
English: Further information on Briviact can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Nadaljnje informacije za zdravilo Briviact so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This was shown in three main studies involving a total of 1,558 patients aged 16 years and above.
Slovenian: To so dokazali v treh glavnih študijah, ki so skupaj vključevale 1 558 bolnikov, starih 16 let in več.
English: Briviact received a marketing authorisation valid throughout the EU on 14 January 2016.
Slovenian: Za zdravilo Briviact je bilo 14. januarja 2016 izdano dovoljenje za promet, veljavno po vsej EU.
English: What measures are being taken to ensure the safe and effective use of Briviact?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Briviact?
English: Therefore Briviact is expected to work in children in the same way.
Slovenian: Zato se pričakuje, da bo zdravilo Briviact pri otrocih delovalo na enak način.
English: The European Medicines Agency decided that Briviact's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Briviact večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: Epilepsy is caused by excessive electrical activity in certain areas of the brain.
Slovenian: Epilepsijo povzroča prekomerna električna dejavnost v določenih predelih možganov.
English: Other information about Briviact
Slovenian: Druge informacije o zdravilu Briviact
English: As for all medicines, data on the use of Briviact are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Briviact stalno spremljajo.
English: It can be used in patients from the age of 4 years with partial-onset seizures with or without secondary generalisation (where the abnormal electrical activity spreads through the brain).
Slovenian: Lahko se uporablja pri bolnikih, starih štiri leta ali več, s parcialnimi epileptičnimi napadi s sekundarno generalizacijo ali brez nje (pri kateri se nenormalna električna aktivnost širi skozi možgane).
English: Most side effects of Briviact were of mild or moderate severity and were considered manageable.
Slovenian: Večina neželenih učinkov zdravila Briviact je bila blagih ali zmernih, ocenjeni pa so bili kot obvladljivi.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Briviact have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Briviact upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: The most common side effects with Briviact (which may affect more than 1 in 10 people) are somnolence (sleepiness) and dizziness.
Slovenian: Najpogostejša neželena učinka zdravila Briviact (ki se lahko pojavita pri več kot 1 od 10 bolnikov) sta somnolenca (zaspanost) in omotica.
English: This compares with 20% in those adding placebo.
Slovenian: Do enakega rezultata je prišlo pri 20 % bolnikov, ki so kot dodatek prejemali placebo.
English: An overview of Briviact and why it is authorised in the EU
Slovenian: Pregled zdravila Briviact in zakaj je odobreno v EU
English: What is Briviact and what is it used for?
Slovenian: Kaj je zdravilo Briviact in za kaj se uporablja?
English: Why is Briviact authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Briviact odobreno v EU?
English: Side effects reported with Briviact are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Briviact, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: Supportive studies showed that the doses recommended for children produced similar amounts of the medicine in the body to those seen with recommended doses in adults.
Slovenian: Podporne študije so pokazale, da so bile s priporočenimi odmerki zdravila pri otrocih dosežene podobne ravni zdravila v telesu kot s priporočenimi odmerki pri odraslih.
English: For more information about using Briviact, see the package leaflet or contact a doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Briviact glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Briviact is available as tablets (10, 25, 50, 75 and 100 mg), an oral solution (10 mg/ml) and a solution for injection or infusion (drip) into a vein (10 mg/ml), which is used when the medicine cannot be given by mouth.
Slovenian: Zdravilo Briviact je na voljo v obliki tablet (10, 25, 50, 75 in 100 mg), peroralne raztopine (10 mg/ml) in raztopine za injiciranje ali infundiranje (kapalna infuzija) v veno (10 mg/ml); ta se uporablja, kadar zdravila ni mogoče dati peroralno.
English: This helps Briviact to stabilise electrical activity in the brain and prevent seizures.
Slovenian: To zdravilu Briviact omogoča, da stabilizira električno aktivnost v možganih in prepreči epileptične napade.
English: What benefits of Briviact have been shown in studies?
Slovenian: Kakšne koristi zdravila Briviact so se pokazale v študijah?
English: The exact way in which brivaracetam, the active substance in Briviact, works is not clear but it attaches to a protein called synaptic vesicle protein 2A, which is involved in the release of chemical messengers from nerve cells.
Slovenian: Natančen način delovanja brivaracetama, učinkovine v zdravilu Briviact, ni jasen, znano pa je, da se pritrdi na beljakovino, imenovano sinaptični vezikularni protein 2A, ki sodeluje pri sproščanju kemičnih
English: What are the risks associated with Briviact?
Slovenian: Kakšna tveganja so povezana z zdravilom Briviact?
English: Briviact is an epilepsy medicine used as an add-on to other epilepsy medicines to treat partial-onset seizures (epileptic fits starting in one specific part of the brain).
Slovenian: Briviact je zdravilo za epilepsijo, ki se uporablja poleg drugih zdravil za epilepsijo kot dodatno zdravilo za zdravljenje parcialnih epileptičnih napadov (epileptičnih napadov, ki se začnejo v določenem delu možganov).
English: Briviact must not be used in patients who are hypersensitive (allergic) to brivaracetam, to other pyrrolidone derivatives (substances that are chemically similar to brivaracetam), or to any of the other ingredients.
Slovenian: Zdravila Briviact ne smejo uporabljati bolniki, ki so preobčutljivi za (alergični na) brivaracetam, druge derivate pirolidona (snovi, ki so kemično podobne brivaracetamu) ali katero koli drugo sestavino zdravila.
English: The recommended starting dose in adults and younger patients weighing more than 50 kg is either 25 mg twice a day or 50 mg twice a day, depending on the patient's condition.
Slovenian: Priporočeni začetni odmerek pri odraslih in mlajših bolnikih, ki tehtajo več kot 50 kg, je bodisi 25 mg dvakrat na dan ali 50 mg dvakrat na dan, odvisno od bolnikovega stanja.
English: Taking the studies together, the frequency of seizures was at least halved in 34 to 38% of those adding Briviact at doses from 25 to 100 mg twice a day.
Slovenian: V vseh študijah skupaj je bila pogostnost epileptičnih napadov pri 34 do 38 % bolnikov, ki so kot dodatek prejemali zdravilo Briviact v odmerku med 25 in 100 mg dvakrat na dan, najmanj prepolovljena.
English: (brivaracetam)
Slovenian: Briviact1 (brivaracetam)
English: Briviact contains the active substance brivaracetam.
Slovenian: Zdravilo Briviact vsebuje učinkovino brivaracetam.
English: Clinical studies have shown add-on treatment with Briviact to be more effective than placebo for controlling partial-onset seizures in adults and children from 4 years of age.
Slovenian: Klinične študije so pokazale, da je dodatno zdravljenje z zdravilom Briviact pri nadzoru parcialnih epileptičnih napadov pri odraslih in otrocih, starih štiri leta ali več, učinkovitejše od placeba.
English: How is Briviact used?
Slovenian: Kako se zdravilo Briviact uporablja?
English: Briviact is more effective than placebo (a dummy treatment) at reducing seizures.
Slovenian: Zdravilo Briviact je pri zmanjševanju epileptičnih napadov učinkovitejši od placeba (zdravila brez učinkovine).
English: How does Briviact work?
Slovenian: Kako zdravilo Briviact deluje?
English: For the full list of side effects of Briviact, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Briviact, glejte navodilo za uporabo.
English: Either Briviact or placebo was added to patients' usual epilepsy treatment.
Slovenian: Bolniki so poleg običajnega zdravila za epilepsijo prejeli še zdravilo Briviact ali placebo.
English: In those weighing less than 50 kg the dose is based on body weight and the usual starting dose is 0.5 mg per kg body weight twice a day.
Slovenian: Pri bolnikih, ki tehtajo manj kot 50 kg, se odmerek določi glede na telesno maso, običajni začetni odmerek pa je 0,5 mg na kg telesne mase dvakrat na dan. Odmerek se lahko prilagodi glede na bolnikove potrebe do največ 100 mg oziroma 2 mg na kg telesne mase dvakrat na dan.
English: Your doctor will tell you how long you should continue to take PROTELOS.
Slovenian: Zdravnik vam bo povedal, koliko časa morate jemati PROTELOS.
English: Your doctor will not prescribe PROTELOS for you if you are at particular risk.
Slovenian: Vaš zdravnik vam ne bo predpisal zdravila PROTELOS, če ste še posebej ogroženi.
English: You can take PROTELOS again when you have finished taking these antibiotics.
Slovenian: PROTELOS lahko ponovno začnete jemati, ko prenehate z jemanjem tovrstnih antibiotikov.
English: PROTELOS has been studied in clinical trials involving nearly 8,000 participants.
Slovenian: PROTELOS so proučevali v kliničnih študijah, ki so zajele skoraj 8000 bolnikov.
English: What protelos is and what it is used for
Slovenian: Kaj je zdravilo PROTELOS in za kaj ga uporabljamo
English: Children and adolescents PROTELOS is not intended for use in children and adolescents (below the age of 18).
Slovenian: PROTELOS ni namenjen otrokom in mladostnikom (mlajšim od 18 let).
English: In each Member State where PROTELOS is marketed, the Marketing Authorisation Holder (MAH) shall agree the final educational programme with the National Competent Authority.
Slovenian: V posamezni državi članici, kjer se zdravilo PROTELOS trži, se mora imetnik dovoljenja za promet z zdravilom (MAH) dogovoriti s pristojnim nacionalnim organom o končnem izobraževalnem programu.
English: Pharmacokinetics in special clinical situations
Slovenian: Farmakokinetika pri posebnih kliničnih skupinah
English: Like all medicines, this medecine can cause side effects, although not everybody gets them.
Slovenian: Kot vsa zdravila ima lahko tudi to zdravilo neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
English: If you are of Asian origin, talk to your doctor before taking PROTELOS as you may be at higher risk of skin reactions.
Slovenian: Če ste azijskega porekla, se pred začetkom jemanja zdravila PROTELOS posvetujte s svojim zdravnikom, ker je pri vas tveganje za kožne reakcije lahko večje.
English: Rare: Severe hypersensitivity reactions (DRESS: see section 2)
Slovenian: Redki: Hude preobčutljivostne reakcije (sindrom DRESS: glejte poglavje 2).
English: If you have stopped treatment due to hypersensitivity reactions, do not take PROTELOS again
Slovenian: Če ste prenehali z zdravljenjem zaradi preobčutljivostnih reakcij, zdravila PROTELOS ne jemljite več.
English: EU/1/04/288/001 EU/1/04/288/002 EU/1/04/288/003 EU/1/04/288/004 EU/1/04/288/005
Slovenian: EU/1/04/288/001 EU/1/04/288/002 EU/1/04/288/003 EU/1/04/288/004 EU/1/04/288/005 EU/1/04/288/006
English: It is recommended that you take PROTELOS in-between meals, preferably at bedtime at least two hours after food, milk or milk products or calcium supplements.
Slovenian: PROTELOS jemljete v času med dvema obrokoma, najbolje pred spanjem, najmanj dve uri po zaužitju hrane, mleka ali mlečnih izdelkov in dodatkov kalcija.
English: Heart attack may occur commonly in patients at high risk for heart disease.
Slovenian: Pogosti: Srčni infarkt lahko pogosto nastopi pri bolnikih z visokim tveganjem za bolezen srca.
English: If you forget to take PROTELOS:
Slovenian: Če ste pozabili vzeti zdravilo PROTELOS
English: You should stop taking PROTELOS if you have to take oral tetracyclines or quinolones (two types of antibiotics).
Slovenian: - Prenehajte jemati PROTELOS, če se zdravite s peroralnimi tetraciklini ali kinoloni (dve vrsti antibiotikov).
English: Other medicines and PROTELOS:
Slovenian: Druga zdravila in zdravilo PROTELOS
English: Given the slow absorption, PROTELOS should be taken at bedtime, preferably at least two hours after eating (see sections 4.5 and 5.2).
Slovenian: Zaradi počasne absorpcije PROTELOS jemljemo pred spanjem, najbolje najmanj dve uri po obroku (glejte poglavji 4.5 in 5.2).
English: The frequency of possible side effects listed below is defined using the following convention: very common: may affect more than 1 in 10 people common:may affect up to 1 in 10 people uncommon: mayaffect up to 1 in 100 people rare: mayaffect up to 1 in 1,000 people very rare: mayaffect up to 1 in 10,000 people not known: frequency cannot be estimated from the available data
Slovenian: Pogostnost možnih spodaj navedenih neželenih učinkov je definirana z uporabo naslednjega dogovora: zelo pogosti: pojavijo se lahko pri več kot 1 od 10 bolnikov pogosti: pojavijo se lahko pri največ 1 od 10 bolnikov občasni: pojavijo se lahko pri največ 1 od 100 bolnikov redki: pojavijo se lahko pri največ 1 od 1.000 bolnikov zelo redki: pojavijo se lahko pri največ 1 od 10.000 bolnikov neznana pogostnost: pogostnosti iz razpoložljivih podatkov ni mogoče oceniti
English: During treatment, if you experience an allergic reaction (such as swelling of the face, tongue or throat, difficulty in breathing or swallowing, skin rash), you must immediately stop taking PROTELOS and seek medical advice.
Slovenian: Če med zdravljenjem doživite hude alergijske reakcije (kot so zatekanje obraza, jezika ali grla, težave pri dihanju ali požiranju, kožni izpuščaj), morate nemudoma prenehati z jemanjem zdravila PROTELOS in poiskati zdravniško pomoč.
English: - If you are taking medicines containing calcium, you should leave at least 2 hours before you take PROTELOS.
Slovenian: - Če jemljete zdravila, ki vsebujejo kalcij, je priporočljivo počakati najmanj 2 uri, preden boste vzeli PROTELOS.
English: PROTELOS is a non-hormonal medicine used to treat severe osteoporosis: - in postmenopausal women, - in men, at high risk of fracture, for whom other alternative treatments are not possible.
Slovenian: PROTELOS je nehormonsko zdravilo za zdravljenje hude osteoporoze: - pri ženskah po menopavzi, - pri moških, z visokim tveganjem za zlome, pri katerih druga alternativna zdravljenja niso mogoča.
English: PROTELOS is for oral use.
Slovenian: PROTELOS je namenjen za peroralno uporabo.
English: PROTELOS works by reducing bone breakdown and stimulating rebuilding of bone and therefore reduces the risk of fracture.
Slovenian: PROTELOS deluje tako, da zmanjšuje razgradnjo kosti in spodbuja njeno gradnjo, s čimer zmanjšuje tveganje za zlome.
English: How PROTELOS works
Slovenian: Kako PROTELOS deluje